Literature DB >> 10987293

Applicability of carcinoembryonic antigen-specific monoclonal antibodies to radioimmunoguided surgery for human colorectal carcinoma.

J C Kim1, W S Kim, J S Ryu, S J Oh, D H Lee, K H Koo, S A Roh, H C Kim, C S Yu, G H Kang, W F Bodmer.   

Abstract

Two carcinoembryonic antigen (CEA)-specific monoclonal antibodies (MAbs), PR1A3 and T84.66, were tested to determine whether they could accurately localize colorectal carcinoma and therefore be applicable in radioimmunoguided surgery (RIGS). Twenty-one tumors by three human colorectal carcinoma cell lines with various levels of CEA expression (KM-12c, C75, and Clone A) were successfully implanted in the intra-abdominal organs of 15 nude mice. The tumors was localized using a portable radioisotope detector (Neoprobe 1000) 48 h after injection of radiolabeled MAbs (10 mCi/mouse) when the precordial counts were <20 per 2 s. Histopathological identification of radiolabeled MAbs were also performed using immunohistochemistry and microautoradiography. Radioactivity counted on a portable radioisotope detector correlated well with that on a gamma counter. The distribution in the blood was significantly greater than in other organs (P < 0.001). Localization indices of the tumor in various organs was from 1.1 to 8.5 in the PR1A3-pretreated mice and 3.0 to 8.6 in the T84.66-pretreated mice. Silver grains and immune staining were distributed in the tumor cells of the PR1A3-pretreated mice, whereas they were in the necrotic debris as well as the tumor cells of the T84.66-pretreated mice. There were significantly more silver grains in the liver in the T84.66-pretreated mice than in the PR1A3-pretreated mice (P = 0.004). The sensitivity and specificity of tumor localization by RIGS were 71.4 and 91.4% in the PR1A3-pretreated mice, whereas they were 60 and 76% in the T84.66-pretreated mice. A study using specific anti-CEA MAbs suggested PR1A3 as an efficient immune probe for RIGS in colorectal carcinoma with a low rate of false-positive detection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987293

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  Recent trends in antibody-based oncologic imaging.

Authors:  Sukhwinder Kaur; Ganesh Venktaraman; Maneesh Jain; Shantibhusan Senapati; Pradeep K Garg; Surinder K Batra
Journal:  Cancer Lett       Date:  2011-10-20       Impact factor: 8.679

2.  Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study.

Authors:  A P Zbar; H Thomas; R W Wilkinson; M Wadhwa; K N Syrigos; E L Ross; P Dilger; T G Allen-Mersh; W A Kmiot; A A Epenetos; D Snary; W F Bodmer
Journal:  Int J Colorectal Dis       Date:  2005-04-30       Impact factor: 2.571

3.  Experimental radioimmunoguided surgery for peritoneal metastases of gastric cancer using anticarcinoembryonic antigen-specific T84.66 F(ab')2.

Authors:  Jin C Kim; Hyun K Hong; Kang H Lee; In H Ka; Seon A Roh; Kum H Koo; Hee C Kim; Seong T Oh; Seong J Oh; Jung S Kim; Kun C Park
Journal:  J Cancer Res Clin Oncol       Date:  2005-05-11       Impact factor: 4.553

4.  Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein.

Authors:  Emiliano Pavoni; Michela Flego; Maria Luisa Dupuis; Stefano Barca; Fiorella Petronzelli; Anna Maria Anastasi; Valeria D'Alessio; Angela Pelliccia; Paola Vaccaro; Giorgia Monteriù; Alessandro Ascione; Rita De Santis; Franco Felici; Maurizio Cianfriglia; Olga Minenkova
Journal:  BMC Cancer       Date:  2006-02-24       Impact factor: 4.430

Review 5.  Current approaches and challenges for monitoring treatment response in colon and rectal cancer.

Authors:  Elizabeth McKeown; Daniel W Nelson; Eric K Johnson; Justin A Maykel; Alexander Stojadinovic; Aviram Nissan; Itzhak Avital; Björn Ldm Brücher; Scott R Steele
Journal:  J Cancer       Date:  2014-01-01       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.